Targets › HPV16
16 programs from 13 companies in 22 trials: 10 Phase 3, 6 Phase 4, 3 Phase 2, 3 Phase 1; Infectious disease, Oncology, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: the race on HPV16, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Miquel Angel Pavon Ribas | Nonavalent HPV vaccine (9vHPV/Gardasil-9™) Virus-like particles (VLPs) of HPV major capsid L1 protein from 9 HPV types that generate | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 4 | Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) | Dec 2026 |
| National Cancer Institute (NCI) | Recombinant Human Papillomavirus Bivalent Vaccine Bivalent HPV vaccine (HPV 16/18 L1 VLP/AS04) | HPV16, HPV18 | Phase 4 | Human Papillomavirus-Related Cervical Carcinoma; Human Papillomavirus Infection | Jan 2027 |
| The University of Texas Medical Branch, Galveston | 9-valent HPV vaccine, 2 doses alternate timing Recombinant human papillomavirus vaccine targeting 9 HPV types | HPV5, HPV6, HPV11, HPV16, HPV18 | Phase 4 | Immunization | Aug 2027 |
| International Agency for Research on Cancer | CERVAVAC quadrivalent HPV vaccine Quadrivalent HPV vaccine targeting HPV types 6, 11, 16, and 18 | HPV6, HPV11, HPV16, HPV18 | Phase 4 | Vaccine Effectiveness | Dec 2028 |
| Erasmus Medical Center | Gardasil 9 Suspension for Injection Nonavalent HPV vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58 | HPV5, HPV11, HPV16, HPV18 | Phase 4 | Vulvar HSIL | Dec 2028 |
| Merck & Co. (MSD) | 9-valent human papillomavirus (9vHPV) vaccine (Types 6, 11, 16, 18, 31, 33, 45, Aluminum-adjuvanted recombinant protein vaccine containing virus-like particles of recombi | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Papillomavirus Infections; Genital Warts | Jan 2027 |
| Shanghai Bovax Biotechnology | 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recom 9-valent HPV recombinant vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Genital Wart; Cervical Cancer | Jul 2027 |
| Xiamen University | Nonavalent HPV vaccine (6,11,16,18,31,33,45,52,58 Type) Recombinant human papillomavirus vaccine targeting 9 HPV types | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Cervical Intraepithelial Neoplasia | Dec 2027 |
| Beijing Health Guard Biotechnology | Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (H Recombinant nonavalent HPV vaccine targeting 9 HPV types | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Human Papillomavirus Infection | Mar 2028 |
| National Vaccine and Serum Institute, China | Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) Recombinant human papillomavirus vaccine (HPV types 6, 11, 16, 18) | HPV6, HPV11, HPV16, HPV18 | Phase 3 | Human Papillomavirus (HPV) Infection | Jul 2032 |
| Washington University School of Medicine | CUE-101 HPV16-targeted immunotherapy, likely E6/E7-targeted T-cell therapy | HPV16 | Phase 2 | Oropharyngeal Squamous Cell Carcinoma | Oct 2027 |
| PapiVax Biotech, Inc. | pBI-4 DNA vaccine HPV16 therapeutic DNA vaccine | HPV16 | Phase 2 | Cervical Intraepithelial Neoplasia Grade 2/3 | Dec 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | pBI-11 HPV16/18-targeted therapeutic DNA vaccine | HPV16, HPV18 | Phase 2 | HPV Infection | Nov 2028 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | pNGVL4aCRTE6E7L2 HPV16 DNA vaccine encoding E6 and E7 antigens with electroporation delivery | HPV16, E6, E7 | Phase 1 | Human Papillomavirus Type 16 | Dec 2027 |
| National Cancer Institute (NCI) | HPV16 RG1 VLP Vaccine Recombinant virus-like particle (VLP) vaccine targeting HPV type 16 with modified structur | HPV16 | Phase 1 | Human Papillomavirus-Related Carcinoma | Feb 2028 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | PVX7 Therapeutic HPV vaccine (pBI-11 DNA + TA-HPV) | HPV16, HPV18 | Phase 1 | Cervical Cancer | Jun 2029 |
Papillomavirus Infections (4) Human Papillomavirus Infection (2) Cervical Cancer (2) Genital Warts (1) Cervical Intraepithelial Neoplasia (1) Immunization (1) HPV Infection (1) Human Papillomavirus-Related Cervical Carcinoma (1) Oropharyngeal Squamous Cell Carcinoma (1) Human Papillomavirus-Related Carcinoma (1) Vulvar HSIL (1) Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) (1)
other (8), small molecule (4), mixed (2), protein or peptide (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) National Cancer Institute (NCI) (2) Merck & Co. (MSD) (1) Xiamen University (1) The University of Texas Medical Branch, Galveston (1) Beijing Health Guard Biotechnology (1) Washington University School of Medicine (1) Erasmus Medical Center (1) Miquel Angel Pavon Ribas (1) Shanghai Bovax Biotechnology (1) PapiVax Biotech, Inc. (1) International Agency for Research on Cancer (1) National Vaccine and Serum Institute, China (1)
HPV18 (12) HPV11 (9) HPV6 (8) HPV31 (5) HPV5 (2) E6 (1) E7 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.